益肾调肝方治疗乳腺癌患者类更年期综合征肝肾阴虚证的临床研究

Clinical research of kidney-reinforcing and liver-regulating formula in treating breast cancer patients with perimenopausal syndrome

目的观察益肾调肝方对乳腺癌患者类更年期综合征证候群的治疗作用及安全性。方法将60例符合入选标准的乳腺癌患者,随机分为治疗组和对照组。治疗组予益肾调肝方口服,对照组予更年安胶囊口服。比较两组病人更年期综合征症状积分、临床主症症状积分、生活质量、雌激素水平、卵泡刺激素水平以及药物不良反应等指标。结果治疗组与对照组在治疗后更年期综合征症状、临床主症、生活质量改善方面均优于治疗前(P<0.05),但治疗组效果优于对照组(P<0.05);治疗组在临床主症的改善方面以潮热汗出、烦躁易怒尤为明显,改善率分别为96.67%和93.33%;两组患者治疗前后雌激素及卵泡刺激素水平均无明显变化(P>0.05)。两组治疗前后白细胞、血小板、血红蛋白计数比较均无统计学差异(P>0.05),两组均未出现明显肝肾功能、心电图方面异常。结论益肾调肝方治疗乳腺癌合并类更年期综合征疗效肯定,无明显不良反应。

Objective To observe the therapeutic effects and security of kidney-reinforcing and liver-regulating formula in treating breast cancer patients with perimenopausal syndrome. Methods 60 breast cancer patients who matched the criteria were randomly divived into treatment group and control group. Treating group was treated with kidney-reinforcing and liver-regulating formula, while control group was given Gengnian An capsule. Premenopausal syndrome symptom score, the main clinical symptom score, quality of life, the level of estrogen, follicle-stimulating hormone affects and adverse affects were observed to evaluate the effects in 2 groups. Results After treat- ment, the syndrome symptoms, the main clinical symptoms and the quantity of life were improved in both groups（P〈0.05）, and the effects in treatment group were more obvious than in control group （P〈0.05）. In treatment group, the main clinical symptoms were ameliorated after treatment, especially the hectic fever and sweating and irritability, of which the symptom improvement rate were 96.67% and 93.33% respectively. After treatment, both groups had no significant changes in estrogen and